Market capitalization | €471.42m |
P/E (TTM) P/E ratio | negative |
P/S ratio (TTM) P/S ratio | 1.78 |
Revenue growth (TTM) Revenue growth | 17.86% |
Revenue (TTM) Revenue | €264.64m |
EBIT (operating result TTM) EBIT | €-5.08m |
Free Cash Flow (TTM) Free Cash Flow | €-60.32m |
EPS (TTM) EPS | €-0.19 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.
8 Analysts have issued a Valneva forecast:
8 Analysts have issued a Valneva forecast:
Mar '25 |
+/-
%
|
||
Revenue | 265 265 |
18%
18%
|
|
Gross Profit | 117 117 |
46%
46%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -5.08 -5.08 |
96%
96%
|
Net Profit | -31 -31 |
60%
60%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.
Head office | France |
CEO | Thomas Lingelbach |
Employees | 713 |
Founded | 1999 |
Website | valneva.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.